Podium to Practice: ESMO® 2026 – GU: XmAb819
OR
Studies / Trials Discussed
3588O – Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
3588O – Phase 1 results of XmAb819, a novel ENPP3 x CD3 bispecific, in advanced clear cell renal cell carcinoma (ccRCC)
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.